Palbociclib 125mg Capsules contain palbociclib 125mg, an oral prescription cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used as targeted treatment for adults with hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant following progression after endocrine therapy.
Palbociclib works by inhibiting CDK4 and CDK6, proteins involved in cell-cycle progression. By interfering with these pathways, it can slow the proliferation of susceptible breast cancer cells. The 125mg capsule is the established starting strength, with treatment generally administered once daily for 21 consecutive days followed by 7 days off, forming a 28-day cycle.
Ibrance® is the reference brand containing palbociclib. Palbociclib 125mg Capsules are prescription oncology medicines and should be used under the supervision of a qualified oncologist.
Palbociclib is an oral targeted anticancer medicine belonging to the CDK4/6 inhibitor class.
CDK4 and CDK6 are enzymes involved in controlling the progression of cells through the cell cycle. In certain breast cancers, increased activity of these pathways contributes to continued cancer-cell proliferation.
Palbociclib inhibits CDK4 and CDK6, helping interfere with cell-cycle progression and limiting the multiplication of susceptible cancer cells. This targeted mechanism distinguishes palbociclib from traditional cytotoxic chemotherapy.
Palbociclib is primarily used for adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
Approved treatment combinations include:
The appropriate endocrine partner depends on the patient’s treatment history, menopausal status, disease characteristics and prescribing information applicable to the country.
Palbociclib selectively inhibits cyclin-dependent kinases 4 and 6.
CDK4/6 activity helps regulate progression through the cell cycle. Blocking these enzymes can prevent susceptible cancer cells from progressing normally through the cell cycle, thereby reducing cancer-cell proliferation.
This makes palbociclib a targeted cell-cycle therapy used particularly in hormone receptor-positive breast cancer.
Palbociclib has an established role in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
It is generally administered together with endocrine therapy rather than used as conventional chemotherapy. Depending on the treatment setting, the endocrine partner may be an aromatase inhibitor or fulvestrant.
The principal treatment relationship is:
Palbociclib 125mg → Palbociclib Capsules → Generic Ibrance 125mg → CDK4/6 Inhibitor → HR-Positive HER2-Negative Breast Cancer → Targeted Breast Cancer Treatment
Ibrance® contains palbociclib and is the established reference brand marketed by Pfizer. Pfizer’s current product information lists Ibrance in 75mg, 100mg and 125mg capsule strengths.
Palbociclib 125mg is therefore commonly searched alongside terms such as Ibrance 125mg, Generic Ibrance 125mg, Palbociclib 125mg Generic, Palbociclib 125mg Capsules and Ibrance 125mg Alternative.
The recommended starting dose for the capsule formulation is 125mg once daily for 21 consecutive days followed by 7 days off treatment, completing a 28-day cycle. Ibrance capsules should be taken with food and swallowed whole.
Dose interruptions or reductions may be necessary depending on blood counts, adverse reactions, drug interactions and individual tolerability.
Patients should follow the dosage and schedule prescribed by their oncologist and should not independently change or discontinue treatment.
Palbociclib can cause adverse reactions and requires medical monitoring.
Common adverse effects include:
Neutropenia is one of the most clinically important adverse effects associated with palbociclib. Regular blood-count monitoring is therefore an important part of treatment.
Rare but serious interstitial lung disease/pneumonitis has also been reported. New or worsening respiratory symptoms should be reported promptly to a healthcare professional.
Treatment with palbociclib generally requires regular medical monitoring, including:
The prescribing information recommends complete blood-count monitoring before treatment and at specified points during treatment, particularly during the initial cycles.
Palbociclib also has clinically important drug interactions. Grapefruit products and strong CYP3A inhibitors or inducers may affect palbociclib exposure and should be discussed with the treating healthcare professional.
Palbociclib is commonly combined with endocrine therapy for HR-positive breast cancer.
Depending on the indication, treatment can include:
The appropriate combination is selected according to the patient’s cancer characteristics, previous treatment and clinical circumstances.
Palbociclib 125mg Capsules are prescription oncology medicines supplied for eligible patients under medical supervision.
Customers searching for Palbociclib 125mg Capsules, Palbociclib 125mg, Generic Palbociclib 125mg, Generic Ibrance 125mg, Ibrance 125mg, Buy Palbociclib 125mg, Buy Palbociclib Online, Palbociclib 125mg Price, Palbociclib Supplier, Palbociclib 125mg Online, Ibrance Alternative and related commercial terms can find the product through appropriately licensed pharmacies or authorized pharmaceutical suppliers.
Availability, prescription requirements, import regulations and dispensing requirements vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Palbociclib 125mg is used with endocrine therapy for eligible adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
The generic name is palbociclib.
Ibrance is the reference brand containing palbociclib. An appropriately authorized palbociclib product contains the same active pharmaceutical ingredient, although the manufacturer, formulation and regulatory status can vary.
Yes. Palbociclib is an oral CDK4/6 inhibitor that blocks CDK4 and CDK6 activity involved in cell-cycle regulation.
Palbociclib is primarily used for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with endocrine therapy.
Palbociclib inhibits CDK4 and CDK6, interfering with cell-cycle progression and slowing the proliferation of susceptible cancer cells.
The standard capsule starting regimen is 125mg once daily for 21 consecutive days followed by 7 days off treatment. Capsules should be taken with food and swallowed whole.
Yes. Complete blood counts are monitored during treatment because palbociclib can cause significant neutropenia and other blood-cell abnormalities.
Yes. Palbociclib is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for eligible patients.
Yes. Palbociclib is indicated with fulvestrant for eligible patients with disease progression following endocrine therapy.
Palbociclib is a prescription anticancer medicine and should be obtained through an appropriately licensed pharmacy or authorized pharmaceutical supplier.
Common adverse effects include neutropenia, leukopenia, infections, fatigue, nausea and anemia. Regular medical monitoring is important during treatment.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Palbociclib is a prescription anticancer medicine requiring specialist oncology supervision. Treatment selection, dosage, combination therapy, monitoring and approved indications depend on the patient’s cancer subtype and clinical circumstances and may vary by country. Palbociclib can cause serious adverse reactions, particularly neutropenia and infections, and rare cases of interstitial lung disease/pneumonitis have been reported. Always follow the official prescribing information for the specific product and consult a qualified oncologist before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Palbociclib 125mg Capsules
Reviews
There are no reviews yet